Jubilant Biosys Limited Announces New CIRC Center to Support Expanded Discovery

Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry and in-vitro ADME Service offerings.
By: Jubilant Biosys
 
SAN DIEGO - Dec. 2, 2021 - PRLog -- Jubilant Biosys provides services for Turning Point Therapeutics Inc. for multiple small molecule oncology research programs. Turning Point is a precision oncology company developing next-generation therapies that target genetic drivers of cancer.

Services for Turning Point Therapeutics Inc. will be conducted out of Jubilant Biosys Limited's newly built state-of-the-art Chemistry Innovation Research Center (CIRC) in Greater Noida, India. Its Chemistry Innovation Research Center has an initial capacity of 500 FTEs enabling higher operational performance for discovery chemistry services and also rapid turn-around of in-vitro ADME data for client projects.

Commenting on this expansion, Giuliano Perfetti, Chief Executive Officer, Jubilant Biosys Limited said, "We are delighted to unveil our newly built Chemistry Innovation Research Center, Greater Noida for Turning Point's and our other clients' project needs and we are looking forward to accelerating their programs through this site."

"We are excited to continue our relationship with Jubilant Biosys Limited as they start using their CIRC. They continue to provide skilled contract services for challenging synthetic chemistry projects while realizing the importance of short cycle times to deliver and provide critical in-vitro ADME (https://www.jubilantbiosys.com/services/dmpk/) data for our growing portfolio," said Siegfried Reich, Ph.D., chief scientific officer, Turning Point Therapeutics.

About Jubilant Biosys Limited:
Jubilant Biosys Limited, a subsidiary of Jubilant Pharmova Limited, an integrated global pharmaceutical company, has a presence in Bengaluru and Noida in India. Jubilant Biosys offers contract research & development services for global pharmaceutical innovators. Jubilant Biosys has demonstrated expertise in functional services in chemistry including computational, medicinal/ synthetic chemistry, PR&D and GMP scale-up capabilities up to phase II. Services in biology include structural biology, in-vitro biology, DMPK, in-vivo pharmacology and Toxicology.

For more info: https://www.jubilantbiosys.com/
Business Development Contact: Ravichandran S
bd@jubilantbiosys.com

About Turning Point Therapeutics:
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients.

For more information, visit www.tptherapeutics.com
Media Contact: Scott Lipman
ir@tptherapeutics.com
858-876-3985
End
Email:***@jubilantbiosys.com
Phone:9258889113
Tags:ADME services
Industry:Biotech
Location:San Diego - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Dignitas Digital PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share